Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zp Spv 3 K/S currently maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This arrangement shows that the company's current pending matters are handled by different examiners in different specialized units rather than being centralized.
The busiest examiner for this portfolio is DABKOWSKI, ERINNE R, who is managing 1 pending office action. This accounts for 1 of the 2 total pending actions. With 2 distinct examiners involved, each one is responsible for 1 of the pending matters, ensuring that the workload is split evenly between the two assigned officials.
For a practitioner, the involvement of 2 distinct art units means that the 2 pending office actions may involve different biological or pharmaceutical sub-fields. Success in these matters will depend on navigating the specific expectations of DABKOWSKI, ERINNE R and the other assigned examiner. Because the actions are in 2 distinct art units, the practitioner must be mindful of the different examination standards that might apply to each individual case.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637392 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | COFFA, SERGIO | 3d overdue |
| 18016490 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | DABKOWSKI, ERINNE R | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18016490 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | DABKOWSKI, ERINNE R | 1654 | §103§112DP | Non-Final OA | — | Pending | Jan 17, 2023 |
| 17637392 | COMPSTATIN ANALOGUES AND THEIR MEDICAL USES | COFFA, SERGIO | 1658 | §103 | Non-Final OA | 3d overdue | Pending | Feb 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial